Original Agenda
We are actively working with our speakers to confirm their availability for the virtual event. Initial response from our speakers has been very positive, and we are optimistic we will have the new programs ready to share here soon.

Optimising Expression Platforms track banner

Wednesday, 11 November

07:45 Registration and Morning Coffee

OVERCOMING EXPRESSION AND PRODUCTION CHALLENGES

08:30

Chairperson's Remarks

Bjørn Voldborg, MSc, Director, CHO Cell Line Development, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
08:35 Temperature Downshift Modifies Expression of UPR-/ERAD-Related Genes and Enhances Production of a Chimeric Fusion Protein in CHO Cells
Alan Dickson, PhD, Professor of Biotechnology; Director, Centre of Excellence in Biopharmaceuticals, Manchester Institute of Biotechnology, The University of Manchester
09:05 Nanobody: Outstanding Features for Diagnostic and Therapeutic Applications
J. Pablo Salvador, PhD, Research Associate, Nanobiotechnology for Diagnostics Group, CIBER-BBN, Spanish Council for Scientific Research
09:35 Engineering and Expression of Antibodies of Different Isotypes and Specificities for Cancer Immunotherapy
Silvia Crescioli, PhD, Postdoctoral Research Associate, St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London

There is a growing interest in antibodies with enhanced functional attributes for cancer immunotherapy, such as Fc-engineered and glyco-engineered antibodies and different isotypes to the commonly used IgG1 (IgG4, IgE). I will present our flexible platforms for engineering and glyco-engineering antibodies of different isotypes and specificities, and expression in transient and stable systems. I will illustrate how these can also be used for the generation of scFv-Fc and antibody-drug conjugates.

 

10:35 Coffee Break in the Exhibit Hall with Poster Viewing
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark

Glycosylation of therapeutic proteins can have severe implications on activity, half-life, and response. We have engineered a large panel of CHO cell lines for the production of therapeutic proteins with tailor-made glycosylation. Using this panel, we are able to quickly produce defined glycovariants of protein-based drug candidates to screen for the optimal variant to bring into development, thereby improving the likelihood of bringing the optimal candidates into clinical trials.

11:45

Achieving High Expression and Solubility of Recombinant Proteins Using TISIGNER.com

Chun Shen Lim, PhD, Postdoctoral Fellow, Department of Biochemistry, School of Biomedical Sciences, University of Otago

Recombinant protein production is a widely used technique, yet half of these experiments fail at the expression phase and only a quarter of target proteins are successfully purified. We have discovered that the energetics of RNA structure ensembles, that model the 'accessibility' of translation initiation sites, accurately predicts the expression outcomes of 11,430 recombinant protein production experiments in Escherichia coli. We have further discovered that normalised B-factors, that model the 'flexibility' of amino acid residues, accurately predicts the solubility of 12,158 recombinant proteins expressed in Escherichia coli. We have optimised these B-factors, and derived a new set of values for solubility scoring that further improves prediction accuracy. We call this new predictor the ‘Solubility-Weighted Index’ (SWI). We have developed TIsigner (Translation Initiation coding region designer) and SoDoPE (Soluble Domain for Protein Expression) that allows users to choose a protein region of interest for optimising expression and solubility, respectively. The final results will suggest synonymous codon changes within the first few codons of the DNA fragments of interest, meaning that gene optimisation can be done using standard PCR cloning.

12:15

Increased-Throughput Protein Production of Novel Botulinum Neurotoxins

Matthias Ehebauer, PhD, Senior Scientist, Neuroscience R&D, Ipsen Bioinnovation

Ipsen Bioinnovation produces engineered protein neurotoxins to support the discovery and development of novel pharmaceutical botulinum toxins. These have traditionally been produced in batch cultures followed by chromatographic purification. We have increased the throughput of neurotoxin production through expression screening. This was achieved using microbioreactors and magnet-based affinity extraction of target proteins. Selected constructs are then produced in a containment laboratory by batch-extracting up to six toxins from lysate in parallel. Under the constraints of working in a contained setting, we can currently produce 24 novel neurotoxins per month.

13:45 Luncheon Presentation II (Sponsorship Opportunity Available)
14:15 Session Break

EFFECTIVE EXPRESSION AND PRODUCTION OF UNIQUE BIOPRODUCTS

14:30

Chairperson's Remarks

Inês A. Isidro, PhD, Scientist, Animal Cell Technology, iBET Instituto de Biologia Experimental Tecnologica
14:35

Integrating High Cell-Density Cultures with Adapted Laboratory Evolution for Vaccine Production Using Stable Insect Cell Lines

Antonio Roldao, PhD, Head of Cell-Based Vaccines Development Laboratory, Animal Cell Technology Unit, Instituto de Biologia Experimental e Tecnológica ( iBET)
15:05 Presentation to be Announced
15:35 Refreshment Break in the Exhibit Hall with Poster Viewing
16:15

Improving AAV Production in Insect Cells through Metabolic Modulation by Targeted Supplements

Inês A. Isidro, PhD, Scientist, Animal Cell Technology, iBET Instituto de Biologia Experimental Tecnologica

Insect cells are an established platform for production of adeno-associated virus (AAV) vectors for gene therapy, but improved understanding of these cells is still necessary to push towards higher productivities and product quality. Based on one-time additions of supplements known to modulate cell metabolism and on statistical design of experiments, we explored the coordinated effect of baculovirus infection and supplementation on insect cell metabolism, cell cycle distribution, and AAV production.

16:45

Improved LV and AAV Vectors for Targeted Gene Therapy

Irene C. Schneider, Dr., Independent Scholar and Consultant, Irene Schneider Consulting

Viral vectors are already naturally perfect transporters of genomic information. The modifications and their production to become tools or therapeutics changing cell properties ex vivo and in vivo will be discussed. A focus will lie on the use of scFv to transform the natural tropism of lentiviral (LV) and AAV vectors to achieve receptor-targeted transduction of a certain cell type and the use of these vectors in gene therapy.

17:15 Presentation to be Announced
17:45 Networking Reception in the Exhibit Hall with Poster Viewing
18:45 Problem Solving Breakout Discussions*

*Topics to be announced.

19:45 End of Day

Thursday, 12 November

08:00 Registration and Morning Coffee

NIMBLE AND EFFICIENT CLD PLATFORMS

08:30

Chairperson's Remarks

Bernd Voedisch, PhD, Principal Scientist II, Novartis Pharma AG
08:35 KEYNOTE PRESENTATION:

Rapid and Nimble Expression and Production Tools: Lessons Learned over the Past Few Months

Nicola A. Burgess-Brown, PhD, Principal Investigator, Biotechnology, Structural Genomics Consortium
09:05

Use of a Targeted Integration CHO Host for Stable Cell Line Development: Insights & Applications

Mark Trautwein, Dr rer nat, Senior Scientist, Biologics Platform, Bayer AG

Both the chromosomal environment of the integration site as well as the genetic elements of a transgene expression cassette contribute to the degree of high and stable transgene expression. We have used a targeted integration host cell line to study the impact of different alterations in proximal chromosomal environment and different genetic elements of the transgene construct. Examples for applications will be given, including optimization of product-specific expression configurations.

09:35

Cell Line Development for Biologics R&D

Bernd Voedisch, PhD, Principal Scientist II, Novartis Pharma AG

The presentation will highlight approaches and technologies applied for the generation of mammalian cell lines that support biologics projects from target identification and candidate generation to manufacturing.

10:35 Coffee Break in the Exhibit Hall with Poster Viewing
11:15 CLOSING PANEL DISCUSSION:

CLOSING PANEL DISCUSSION: Protein Production Challenges - Methodologies and Strategies for Rapid Response

Panel Moderator:
Richard Altman, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific

There are many challenges in operating protein production labs. This panel focuses on the following topics: initiating projects, basic expression and purification systems, pros and cons for each system, screening platforms, troubleshooting, and how much time should be spent on each system before moving to the next option. In addition to “hands-on” tips, we touch upon strategies on how to manage multiple “top-priority” projects.

Panelists:
Nicola A. Burgess-Brown, PhD, Principal Investigator, Biotechnology, Structural Genomics Consortium

There are many challenges in operating protein production labs. This panel focuses on the following topics: initiating projects, basic expression and purification systems, pros and cons for each system, screening platforms, troubleshooting and how much time should be spent on each system before moving to the next option. In addition to “hands-on” tips, we touch upon strategies on how to manage multiple “top priority” projects.

Mark Trautwein, Dr rer nat, Senior Scientist, Biologics Platform, Bayer AG

There are many challenges in operating protein production labs. This panel focuses on the following topics: initiating projects, basic expression and purification systems, pros and cons for each system, screening platforms, troubleshooting and how much time should be spent on each system before moving to the next option. In addition to “hands-on” tips, we touch upon strategies on how to manage multiple “top priority” projects.

Bernd Voedisch, PhD, Principal Scientist II, Novartis Pharma AG
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
13:15 Dessert Break in the Exhibit Hall with Poster Viewing
14:00 Close of Optimising Expression Platforms
17:00 Dinner Short Course Registration
17:30 Recommended Dinner Short Course*
SC9: Developing Stable Bioformulations: Predicting and Controlling Protein Aggregation

*Separate registration required. See short course page for details.